Market Scenario:
Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used. Other diagnostic procedures, such as laboratory evaluations are also used.
However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others.
Get Exclusive Sample Report @https://www.marketresearchfuture.com/sample_request/5630
Segmentation:
The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.
On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.
On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Intended Audience:
• Pharmaceutical Companies
• Hospitals & Clinics
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities
Key Findings:
The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%
On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022
On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022
Regional Analysis:
South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.
The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.
Key Players in the Americas GERD & NERD Treatment Market
Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.
Get Your Customized Report @https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630
Table of Content:
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 Research Objective 12
2.2 Assumptions & Limitations 12
2.2.1 Assumptions 12
2.2.2 Limitations 12
3 RESEARCH METHODOLOGY
3.1 Research Process 14
3.2 Primary Research 15
3.3 Secondary Research 15
3.4 Market Size Estimation 15
4 MARKET DYNAMICS
4.1 Introduction 18
4.2 Drivers 19
4.2.1 Rising Incidences Of Traumatic Stress And Road Accidents 19
4.2.2 Increasing Cases Of Rheumatic Diseases 20
4.2.3 Growing Awareness Among The Population 21
TOC Continued…!
Get Discount @https://www.marketresearchfuture.com/check-discount/5630
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]